Advertisement

Medical Oncology

, Volume 29, Issue 1, pp 215–218 | Cite as

Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer

  • Motohiro TamiyaEmail author
  • Hidekazu Suzuki
  • Masashi Kobayashi
  • Shinji Sasada
  • Norio Okamoto
  • Naoko Morishita
  • Tomomi Yasue
  • Yuka Matsuura
  • Tomonori Hirashima
  • Ichiro Kawase
Original Paper

Abstract

Bone metastasis is an important factor for determining the appropriate treatment for patients with lung cancer. The cross-linked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of the bone matrix. Urinary NTx is recognized as a useful marker of bone metastasis, but the application of serum NTx and its cutoff value for determining bone metastasis from lung cancer have not been characterized. We measured serum NTx by enzyme-linked immunosorbent assay of individuals who underwent staging during hospitalization for initial treatment of lung cancer in our department and compared the NTx levels with the presence of bone metastasis in staging. The study included 166 patients with lung cancer (128 men and 38 women), including 85 adenocarcinoma, 42 squamous cell carcinoma, 32 small-cell carcinoma, and 7 other cancer types. Bone metastasis was present in 73 cases. The average/median serum NTx of bone metastasis (+) and bone metastasis (−) was 27.8/23.8 and 17.1/16.5 nmol bone collagen equivalents/L, respectively. There was an intentional difference with P < 0.001. The cutoff value of the serum NTx level indicating bone metastasis from lung cancer was estimated using the receiver operating characteristics curve. The optimal cutoff value was found to be 22.0 (sensitivity: 61.6%, specificity: 89.2%). The results of univariate and multivariate analysis revealed that the serum NTx levels were significantly related to bone metastasis from lung cancer (P < 0.001). Measurement of serum NTx levels provides a simple diagnostic marker of bone metastasis from lung cancer.

Keywords

Cross-linked N-telopeptide of type I collagen Bone metastasis NTx Lung cancer 

Notes

Acknowledgments

The authors wish to thank all the patients participated in this study.

Conflict of interest

The authors have no financial arrangements or relationships with any individuals or organizations that could potentially influence this work.

References

  1. 1.
    Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004;34:827–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Perez DJ, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983;2:613–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Pecherstorfer M, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80:97–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Massidda B, et al. Usefulness of pyridinium crosslinks and CA 15–3 as markers in metastatic bone breast carcinoma. Anticancer Res. 1996;16:2221–3.PubMedGoogle Scholar
  7. 7.
    Lipton A, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 1993;39:614–8.PubMedGoogle Scholar
  8. 8.
    Izumi M, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget’s disease of bone. J Clin Endocrinol Metab. 1984;58:110–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone. 2000;26:241–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Blumsohn A, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 1994;79:730–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Lipton A, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201.PubMedCrossRefGoogle Scholar
  14. 14.
    Coleman RE, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.PubMedCrossRefGoogle Scholar
  15. 15.
    De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Yun HK, et al. Laboratory evaluation of bone marrow metastasis: single institute study. Korean J Lab Med. 2007;27:96–101.PubMedCrossRefGoogle Scholar
  17. 17.
    Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994;31:197–293.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Motohiro Tamiya
    • 1
    Email author
  • Hidekazu Suzuki
    • 1
  • Masashi Kobayashi
    • 1
  • Shinji Sasada
    • 1
  • Norio Okamoto
    • 1
  • Naoko Morishita
    • 1
  • Tomomi Yasue
    • 2
  • Yuka Matsuura
    • 1
  • Tomonori Hirashima
    • 1
  • Ichiro Kawase
    • 1
  1. 1.Department of Thoracic MalignancyOsaka Prefectural Hospital Organization, Osaka Prefectural Medical Center for Respiratory and Allergic DiseasesHabikino, OsakaJapan
  2. 2.Department of Laboratory MedicineOsaka Prefectural Hospital Organization, Osaka Prefectural Medical Center for Respiratory and Allergic DiseasesHabikino, OsakaJapan

Personalised recommendations